A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models

Zhang-Yin, Jules; Provost, Claire; Cancel‐Tassin, Géraldine; Rusu, Timofei; Penent, Mallaurie; Radulescu, C.; Compérat, Eva; Cussenot, Olivier; Montravers, F.; Renard-Penna, Raphaële; Talbot, Jean‐Noël; Prignon, Aurélie

doi:10.1016/j.nucmedbio.2020.03.005

Cited by 14 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhang-Yin et al [37] Pre-clinical 68 Ga-AMBA GRPR 68 Ga-AMBA showed good tumor uptake, high tumor-to-background contrast using PC3 cell line.…”

Section: Year Type Of Study Radiotracer Target Commentmentioning

confidence: 99%

“…The first studies regarding the use of GRPRs for PET/CT imaging and treatment of prostate cancer were based on radiolabelled GRPR-agonists, such as 68 Ga-AMBA/ 177 Lu-AMBA. 68 Ga-AMBA showed, in mice xenografted with 22Rv1 prostate cancer cell line, good tumor uptake, and a high tumor-to-background ratio according to Zhang-Yin et al [ 37 ]. In another study 55 Co-NOTA-AMBA in PC3 xenografted mice was superior for PET/CT imaging, compared to 68 Ga-NOTA-AMBA since it showed a better tumor-to-organ ratio [ 38 ].…”

Section: Theranostic Pet Tracersmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer

Filippi

Frantellizzi

Chiaravalloti

et al. 2021

IJMS

View full text Add to dashboard Cite

Metastatic castration-resistant prostate cancer (mCRPC) represents a condition of progressive disease in spite of androgen deprivation therapy (ADT), with a broad spectrum of manifestations ranging from no symptoms to severe debilitation due to bone or visceral metastatization. The management of mCRPC has been profoundly modified by introducing novel therapeutic tools such as antiandrogen drugs (i.e., abiraterone acetate and enzalutamide), immunotherapy through sipuleucel-T, and targeted alpha therapy (TAT). This variety of approaches calls for unmet need of biomarkers suitable for patients’ pre-treatment selection and prognostic stratification. In this scenario, imaging with positron emission computed tomography (PET/CT) presents great and still unexplored potential to detect specific molecular and metabolic signatures, some of whom, such as the prostate specific membrane antigen (PSMA), can also be exploited as therapeutic targets, thus combining diagnosis and therapy in the so-called “theranostic” approach. In this review, we performed a web-based and desktop literature research to investigate the prognostic and theranostic potential of several PET imaging probes, such as 18F-FDG, 18F-choline and 68Ga-PSMA-11, also covering the emerging tracers still in a pre-clinical phase (e.g., PARP-inhibitors’ analogs and the radioligands binding to gastrin releasing peptide receptors/GRPR), highlighting their potential for defining personalized care pathways in mCRPC

show abstract

“…Zhang-Yin et al [37] Pre-clinical 68 Ga-AMBA GRPR 68 Ga-AMBA showed good tumor uptake, high tumor-to-background contrast using PC3 cell line.…”

Section: Year Type Of Study Radiotracer Target Commentmentioning

confidence: 99%

Section: Theranostic Pet Tracersmentioning

confidence: 99%

Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer

Filippi

Frantellizzi

Chiaravalloti

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Even more octamer peptides have been studied with other isotopes, with similar good-but-not-superior results [ 134 , 135 , 136 ]. Cyclic mono or multimeric peptides, labelled with 68 Ga through a chelator, may also prove to have a future, although a head-to-head clinical comparison is still missing [ 57 , 137 , 138 , 139 , 140 ]. Using the chelator as a positive concept in the RGD structure, some researchers even head back to 18 F and investigate 18 F-labelled NOTA-RGD variants [ 141 ].…”

Section: Direct Targeting Of Angiogenesismentioning

confidence: 99%

Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status

Florea

Mottaghy

Bauwens

2021

IJMS

View full text Add to dashboard Cite

Angiogenesis is an active process, regulating new vessel growth, and is crucial for the survival and growth of tumours next to other complex factors in the tumour microenvironment. We present possible molecular imaging approaches for tumour vascularisation and vitality, focusing on radiopharmaceuticals (tracers). Molecular imaging in general has become an integrated part of cancer therapy, by bringing relevant insights on tumour angiogenic status. After a structured PubMed search, the resulting publication list was screened for oncology related publications in animals and humans, disregarding any cardiovascular findings. The tracers identified can be subdivided into direct targeting of angiogenesis (i.e., vascular endothelial growth factor, laminin, and fibronectin) and indirect targeting (i.e., glucose metabolism, hypoxia, and matrix metallo-proteases, PSMA). Presenting pre-clinical and clinical data of most tracers proposed in the literature, the indirect targeting agents are not 1:1 correlated with angiogenesis factors but do have a strong prognostic power in a clinical setting, while direct targeting agents show most potential and specificity for assessing tumour vascularisation and vitality. Within the direct agents, the combination of multiple targeting tracers into one agent (multimers) seems most promising. This review demonstrates the present clinical applicability of indirect agents, but also the need for more extensive research in the field of direct targeting of angiogenesis in oncology. Although there is currently no direct tracer that can be singled out, the RGD tracer family seems to show the highest potential therefore we expect one of them to enter the clinical routine.

show abstract

“…One such target is neurotensin receptor1 (NTSR1), which exhibits high or moderate expression in 92% of PC tumors, including all PSMA-negative tissues, suggesting a potential complementary role in targeted imaging or/and therapy [ 60 ]. Although the value of NTSR1 expression was not assessed in patients with PSMA-negative PET/CT, preclinical in vitro and in vivo studies in PC animal models suggest that PET imaging using specific probes for NTSR1, such as 68 Ga-DOTA-NT-20.3 or 18 F-DEG-VS-NT could represent viable alternative options for selecting therapies targeting NTSR1 in mCRPC patients with limited PSMA expression levels [ 60 , 61 ].…”

Section: Molecular Biomarkersmentioning

confidence: 99%

Biomarkers in Prostate-Specific Membrane Antigen Theranostics

2021

View full text Add to dashboard Cite

Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of 177Lu and other radionuclides in metastatic castration-resistant prostate cancer (mCRPC), it is becoming increasingly important to identify surrogate markers that can help predict which patients are more likely to respond and experience improved survival. This review discusses potential predictors of efficacy of PSMA-targeted radionuclide therapies (TRT) segregated in three major categories: imaging, clinical and molecular.

show abstract

A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models

Cited by 14 publications

References 42 publications

Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer

Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer

Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status

Biomarkers in Prostate-Specific Membrane Antigen Theranostics

Contact Info

Product

Resources

About